Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis

S. Vijaya Bhaskar Reddy, Ajay Wanchu, Madhu Khullar, S. Govindrajan, Pradeep Bambery

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA). The mechanism of action is not fully understood. Nitric oxide (NO) plays an important role in the pathogenesis of RA. Leflunomide has been shown to cause cell specific inhibition of inducible nitric oxide synthase (iNOS) activation in animal models. We carried out this study to determine if there was alteration in NO production in patients with RA. Methods: An 8-week open label study was carried out on patients with adult onset active RA. We measured levels of nitrite and citrulline spectrophotometrically as surrogate markers of NO production. Within-patient serum levels of nitrite and citrulline were compared with leflunomide therapy at three points of time (at 0, 4 and 8 weeks of therapy). Results: Thirty-three patients with active RA were enrolled for this study. These patients were a subset of 63 individuals who are studied for clinical efficacy of leflunomide. Three patients were lost to follow-up. Median nitrite levels were 817.2 (nmol/ml) at the start of therapy and this declined to 440.9 nmol/ml and 301.1 nmol/ml at 4 and 8 weeks of therapy. Median citrulline levels were 649.3 nmol/ml at the start of the study, which declined to 549.2 nmol/ml and 485.4 nmol/ml at 4 and 8 weeks, respectively. Statistically significant decrease in median values for serum nitrite and citrulline levels was documented after 4 weeks of leflunomide therapy (p0.1). Conclusions: Leflunomide inhibits nitric oxide production in patients with active RA. Inhibition of NO synthesis may be one of the mechanisms responsible for the immunomodulatory activity of leflunomide.

Original languageEnglish (US)
Pages (from-to)1085-1090
Number of pages6
JournalInternational Immunopharmacology
Volume5
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

leflunomide
Rheumatoid Arthritis
Nitric Oxide
Citrulline
Nitrites
Therapeutics
Lost to Follow-Up
Nitric Oxide Synthase Type II
Serum
Animal Models

Keywords

  • Leflunomide
  • Nitric oxide
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. / Reddy, S. Vijaya Bhaskar; Wanchu, Ajay; Khullar, Madhu; Govindrajan, S.; Bambery, Pradeep.

In: International Immunopharmacology, Vol. 5, No. 6, 06.2005, p. 1085-1090.

Research output: Contribution to journalArticle

Reddy, S. Vijaya Bhaskar ; Wanchu, Ajay ; Khullar, Madhu ; Govindrajan, S. ; Bambery, Pradeep. / Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. In: International Immunopharmacology. 2005 ; Vol. 5, No. 6. pp. 1085-1090.
@article{71c6b53199b2485d858796280d6ae747,
title = "Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis",
abstract = "Objectives: Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA). The mechanism of action is not fully understood. Nitric oxide (NO) plays an important role in the pathogenesis of RA. Leflunomide has been shown to cause cell specific inhibition of inducible nitric oxide synthase (iNOS) activation in animal models. We carried out this study to determine if there was alteration in NO production in patients with RA. Methods: An 8-week open label study was carried out on patients with adult onset active RA. We measured levels of nitrite and citrulline spectrophotometrically as surrogate markers of NO production. Within-patient serum levels of nitrite and citrulline were compared with leflunomide therapy at three points of time (at 0, 4 and 8 weeks of therapy). Results: Thirty-three patients with active RA were enrolled for this study. These patients were a subset of 63 individuals who are studied for clinical efficacy of leflunomide. Three patients were lost to follow-up. Median nitrite levels were 817.2 (nmol/ml) at the start of therapy and this declined to 440.9 nmol/ml and 301.1 nmol/ml at 4 and 8 weeks of therapy. Median citrulline levels were 649.3 nmol/ml at the start of the study, which declined to 549.2 nmol/ml and 485.4 nmol/ml at 4 and 8 weeks, respectively. Statistically significant decrease in median values for serum nitrite and citrulline levels was documented after 4 weeks of leflunomide therapy (p0.1). Conclusions: Leflunomide inhibits nitric oxide production in patients with active RA. Inhibition of NO synthesis may be one of the mechanisms responsible for the immunomodulatory activity of leflunomide.",
keywords = "Leflunomide, Nitric oxide, Rheumatoid arthritis",
author = "Reddy, {S. Vijaya Bhaskar} and Ajay Wanchu and Madhu Khullar and S. Govindrajan and Pradeep Bambery",
year = "2005",
month = "6",
doi = "10.1016/j.intimp.2004.11.013",
language = "English (US)",
volume = "5",
pages = "1085--1090",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis

AU - Reddy, S. Vijaya Bhaskar

AU - Wanchu, Ajay

AU - Khullar, Madhu

AU - Govindrajan, S.

AU - Bambery, Pradeep

PY - 2005/6

Y1 - 2005/6

N2 - Objectives: Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA). The mechanism of action is not fully understood. Nitric oxide (NO) plays an important role in the pathogenesis of RA. Leflunomide has been shown to cause cell specific inhibition of inducible nitric oxide synthase (iNOS) activation in animal models. We carried out this study to determine if there was alteration in NO production in patients with RA. Methods: An 8-week open label study was carried out on patients with adult onset active RA. We measured levels of nitrite and citrulline spectrophotometrically as surrogate markers of NO production. Within-patient serum levels of nitrite and citrulline were compared with leflunomide therapy at three points of time (at 0, 4 and 8 weeks of therapy). Results: Thirty-three patients with active RA were enrolled for this study. These patients were a subset of 63 individuals who are studied for clinical efficacy of leflunomide. Three patients were lost to follow-up. Median nitrite levels were 817.2 (nmol/ml) at the start of therapy and this declined to 440.9 nmol/ml and 301.1 nmol/ml at 4 and 8 weeks of therapy. Median citrulline levels were 649.3 nmol/ml at the start of the study, which declined to 549.2 nmol/ml and 485.4 nmol/ml at 4 and 8 weeks, respectively. Statistically significant decrease in median values for serum nitrite and citrulline levels was documented after 4 weeks of leflunomide therapy (p0.1). Conclusions: Leflunomide inhibits nitric oxide production in patients with active RA. Inhibition of NO synthesis may be one of the mechanisms responsible for the immunomodulatory activity of leflunomide.

AB - Objectives: Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA). The mechanism of action is not fully understood. Nitric oxide (NO) plays an important role in the pathogenesis of RA. Leflunomide has been shown to cause cell specific inhibition of inducible nitric oxide synthase (iNOS) activation in animal models. We carried out this study to determine if there was alteration in NO production in patients with RA. Methods: An 8-week open label study was carried out on patients with adult onset active RA. We measured levels of nitrite and citrulline spectrophotometrically as surrogate markers of NO production. Within-patient serum levels of nitrite and citrulline were compared with leflunomide therapy at three points of time (at 0, 4 and 8 weeks of therapy). Results: Thirty-three patients with active RA were enrolled for this study. These patients were a subset of 63 individuals who are studied for clinical efficacy of leflunomide. Three patients were lost to follow-up. Median nitrite levels were 817.2 (nmol/ml) at the start of therapy and this declined to 440.9 nmol/ml and 301.1 nmol/ml at 4 and 8 weeks of therapy. Median citrulline levels were 649.3 nmol/ml at the start of the study, which declined to 549.2 nmol/ml and 485.4 nmol/ml at 4 and 8 weeks, respectively. Statistically significant decrease in median values for serum nitrite and citrulline levels was documented after 4 weeks of leflunomide therapy (p0.1). Conclusions: Leflunomide inhibits nitric oxide production in patients with active RA. Inhibition of NO synthesis may be one of the mechanisms responsible for the immunomodulatory activity of leflunomide.

KW - Leflunomide

KW - Nitric oxide

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=17044422072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044422072&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2004.11.013

DO - 10.1016/j.intimp.2004.11.013

M3 - Article

C2 - 15829424

AN - SCOPUS:17044422072

VL - 5

SP - 1085

EP - 1090

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 6

ER -